Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
ID: ALA285518
Max Phase: Preclinical
Molecular Formula: C22H33N3O5S
Molecular Weight: 451.59
Molecule Type: Small molecule
Associated Items:
ID: ALA285518
Max Phase: Preclinical
Molecular Formula: C22H33N3O5S
Molecular Weight: 451.59
Molecule Type: Small molecule
Associated Items:
Canonical SMILES: COC(=O)[C@H](Cc1ccccc1)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCSC)NC=O
Standard InChI: InChI=1S/C22H33N3O5S/c1-15(2)12-18(24-20(27)17(23-14-26)10-11-31-4)21(28)25-19(22(29)30-3)13-16-8-6-5-7-9-16/h5-9,14-15,17-19H,10-13H2,1-4H3,(H,23,26)(H,24,27)(H,25,28)/t17-,18-,19-/m0/s1
Standard InChI Key: FTDSTRQDCPIBEG-FHWLQOOXSA-N
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Activity Type | Relation | Activity value | Units | Action Type | Journal | PubMed Id | doi | Assay Aladdin ID |
---|
Natural Product: No | Oral: No | Chemical Probe: No | Parenteral: No |
Molecule Type: Small molecule | Topical: No | First In Class: No | Black Box: No |
Chirality: No | Availability: No | Prodrug: No |
MESH ID | MESH Heading | EFO IDs | EFO Terms | Max Phase for Indication | References |
---|
Mechanism of Action | Action Type | target ID | Target Name | Target Type | Target Organism | Binding Site Name | References |
---|
Molecular Weight: 451.59 | Molecular Weight (Monoisotopic): 451.2141 | AlogP: 1.29 | #Rotatable Bonds: 14 |
Polar Surface Area: 113.60 | Molecular Species: NEUTRAL | HBA: 6 | HBD: 3 |
#RO5 Violations: 0 | HBA (Lipinski): 8 | HBD (Lipinski): 3 | #RO5 Violations (Lipinski): 0 |
CX Acidic pKa: 12.06 | CX Basic pKa: | CX LogP: 1.83 | CX LogD: 1.83 |
Aromatic Rings: 1 | Heavy Atoms: 31 | QED Weighted: 0.29 | Np Likeness Score: -0.16 |
1. Cavicchioni G, Vertuani G, Scatturin A, Spisani S. (1994) The role of peptide bond in chemotactic for-met-leu-phe-ome focused by depsipeptide analogs, 4 (13): [10.1016/S0960-894X(01)80564-3] |
2. Cavicchioni G, Turchetti M, Spisani S.. (2001) Biological activity in human neutrophils of di-tripeptides, analogues of the chemotactic fMLP., 11 (24): [PMID:11720864] [10.1016/s0960-894x(01)00640-0] |
3. Torino D, Mollica A, Pinnen F, Feliciani F, Spisani S, Lucente G.. (2009) Novel chemotactic For-Met-Leu-Phe-OMe (fMLF-OMe) analogues based on met residue replacement by 4-amino-proline scaffold: synthesis and bioactivity., 17 (1): [PMID:19081258] [10.1016/j.bmc.2008.11.010] |
4. Cavicchioni G, Fraulini A, Falzarano S, Spisani S.. (2009) Oligomeric formylpeptide activity on human neutrophils., 44 (12): [PMID:19748709] [10.1016/j.ejmech.2009.08.010] |
5. Borgnia MJ, Eytan GD, Assaraf YG.. (1996) Competition of hydrophobic peptides, cytotoxic drugs, and chemosensitizers on a common P-glycoprotein pharmacophore as revealed by its ATPase activity., 271 (1): [PMID:8621716] [10.1074/jbc.271.6.3163] |
6. Hayashi R, Miyazaki M, Osada S, Kawasaki H, Fujita I, Hamasaki Y, Kodama H.. (2013) A formyl peptide substituted with a conformationally constrained phenylalanine residue evokes a selective immune response in human neutrophils., 21 (3): [PMID:23276447] [10.1016/j.bmc.2012.11.046] |
Source(2):